Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.
What factors influence the success or failure of immunotherapy treatment in patients with advanced bladder cancer? Why do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback